Alnylam Pharmaceuticals, Inc.
Compositions and methods for inhibiting expression of CD274/PD-L1 gene

Last updated:

Abstract:

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.

Status:
Grant
Type:

Utility

Filling date:

27 Feb 2018

Issue date:

18 Aug 2020